AFT Pharmaceuticals has entered a licensing and development agreement for its Pascomer drug with US-based Timber Pharmaceuticals.
Pascomer treats facial angiofibromas, which are skin lesions associated with tuberous sclerosis, a skin condition. The company said the disease affects 30,000 people
Want to read more? It's easy.
Choose your best value subscription option
Student
Exclusive offer for uni students studying at a New Zealand university (valued at $499).
